Atorvastatin 25% price cut
July 16, 2012
THE generics price war is
continuing to hot up, with an
unnamed atorvastatin sponsor
having initiated a 25% price cut on
the product effective from the
beiginning of December.
Both Alphapharm and Ranbaxy
have distanced themselves from
the move which under the price
disclosure arrangements will affect
all generic Lipitor suppliers.
Alphapharm issued a statement
on Saturday in which it “states
categorically that it is not
responsible for the price cut.
“Alphapharm is interested to
understand the logic and rational
for the cut from the sponsor that
initiated it,” the company said.
Ranbaxy md Alex Evans has also
denied being behind the move,
confirming that the Health
Department had contacted
atorvastatin sponsors late last week
to advise them of the move.
“Let me just confirm this is not
the work of Ranbaxy and we
deplore the further impact this will
have on pharmacy margins in
2013,” Evans said.
According to the Pharma in Focus
newsletter other atorvastatin
sponsors include Apotex, Ascent, Dr
Reddys Laboratories, Generic
Health, Pfizer, Sandoz, STADA,
Spirit, and Southern Cross Pharma.
AstraZeneca’s Crestor
(rosuvastatin) will also be impacted
because its price is linked to that of
the atorvastatin molecule.
The above article was sent to subscribers in Pharmacy Daily's issue from 16 Jul 12To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 16 Jul 12
